



UDENYCA® SUPPLY CHAIN UPDATE

November 14, 2024

Information for UDENYCA Customers:

- Our final packaging contract manufacturing organization has resumed the labeling and packaging process for UDENYCA. All backlogged lots are scheduled to be processed without further interruption or delay. Onbody production has already been completed and pre-filled syringe production is now underway.
- The backlog comprises thirteen lots totaling about 120,000 UDENYCA units and is expected to be completed over the next few weeks, providing more than enough inventory to meet several months of demand based on historical usage rates. We expect to ship these finished product lots as they are completed, ensuring they get to our customers in an expedited fashion and restocking distribution channels as fast as possible.
- Shipping to 3PL will commence the last week of November with stocking at distributors directly thereafter to fulfill clinic and hospital orders.
- The delays in production at the US-based third-party final packaging CMO were related only to their capacity constraints and do not concern availability or supply of the UDENYCA active pharmaceutical ingredient (API), drug product or components of finished product.
- Coherus has made significant progress in bringing an additional final labeling packaging CMO online. Process validation is underway, and process performance qualification is scheduled for December, producing saleable final product by the end of 2024, with commercial supply from that CMO expected to commence in the first quarter of 2025, subject to U.S. Food and Drug Administration (FDA) authorization.
- Coherus is highly focused on ensuring that UDENYCA reaches patients as quickly as possible. We are working closely with all our customers and channel partners to implement plans for rapid UDENYCA distribution and restocking.

Dennis M. Lanfear
Chief Executive Officer
Coherus BioSciences

UDENYCA is a registered trademark of Coherus BioSciences, Inc.
Coherus BioSciences, Inc., 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065

This update contains forward-looking statements and Coherus undertakes no obligation to update or revise any forward-looking statements. For more information, please see the paragraph entitled "Forward-Looking Statements" in Coherus' press release at the following link: <https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-reports-third-quarter-2024-financial-results>